Elsevier

Brain Research

Volume 640, Issues 1–2, 21 March 1994, Pages 195-204
Brain Research

Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro

https://doi.org/10.1016/0006-8993(94)91873-2Get rights and content

Abstract

Cytostatic drugs, like cisplatin, vincristine and taxol, when given to cancer patients may cause peripheral neuropathies. We were interested in the potential neuroprotective effects of neurotrophic factors against such neuropathies. To this aim we studied the effects of these cytostatic agents on sensory fibers located in the dorsal root ganglia (DRG) in vitro and studied whether nerve growth factor (NGF) could reverse the cytostatic induced morphological changes on intact DRG (1 DRG/well, n=10per dose). Neuritogenesis from DRG was measured with an image analysis system following exposure to different concentrations of cytostatic drugs in the presence of 3 ng NGF/ml and cytosine arabinoside (Ara-C, 10−6 M). Relative neurite outgrowth in intact DRG in culture was reduced dose-dependently, (a) by vincristine starting at a dose of 0.4 ng/ml for 2 days (−33% as compared to control; P < 0.001, Student's t-test); (b) by taxol 10 ng/ml (−60%; P< 0.001), and (c) by cisplatin 3 μg/ml (−47%, P < 0.001). Cisplatin also prevented the migration of satellite cells away from the intact DRG along the extending neurites into the well in contrast to control, vincristine, or taxol. To evaluate the neuroprotective potential of NGF in this in vitro cytostatic neuropathy model, we incubated intact DRG with cytostatic agents in combination with increasing amounts of NGF. Neurite outgrowth from DRG treated with vincristine (0.5 ng/ml) + NGF (3 ng/ml) for 2 days was significantly higher (+87%) than after treatment with vincristine + 1 ng NGF/ml (P < 0.001). Neutrite outgrowth from DRG treated with taxol (20 ng/ml) + NGF (3 ng/ml) for 2 days was significantly higher (+ 228%) than after taxol + 1 ng NGF/ml (P < 0.05). Neurotogenesis from DRG treated with cisplatin (2.5 μg/ml) + NGF (3 ng/ml) for 2 days was significantly increased (+105%) compared to treatment with cisplatin + 1 ng NGF/ml (P < 0.001). DRG thus appear to be a very suitable model for studying cytostatic drug-induced neuropathies in vitro and NGF has a clear neuroprotective effect on the vincristine-, taxol-, and cisplatin-induced neuropathies in this in vitro model.

Reference (57)

  • SchectersonL.C. et al.

    Novel roles for neurotrophins are suggested by BDNF and NT-3 mRNA expression in developing neurons

    Neuron

    (1992)
  • SchnappB.J. et al.

    Single microtubules from squid axoplasm support bidirectional movement of organelles

    Cell

    (1985)
  • SquintoS.P. et al.

    trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor

    Cell

    (1991)
  • StoeckelK. et al.

    Specificity of retrograde transport of nerve growth factor (NGF) in sensory neurons: A biochemical and morphological study

    Brain Res.

    (1975)
  • StoeckelK. et al.

    Retrograde axonal transport of nerve growth factor: specificity and biological importance

    Brain Res.

    (1975)
  • YamamotoM. et al.

    Gene expression of high-(p140trk) and low-affinity nerve growth factor receptor (LNGFR) in the adult and aged human peripheral nervous system

    Neurosci. Lett.

    (1993)
  • AlettaJ.M. et al.

    Nerve growth factor regulates both the phosphorylation and steady-state levels of microtubule-associated protein 1.2 (MAP 1.2)

    J. Cell. Biol.

    (1988)
  • ApfelS.C. et al.

    Nerve growth factor prevents experimental cisplatin neuropathy

    Ann. Neurol.

    (1992)
  • ApfelS.C. et al.

    Nerve growth factor prevents toxic neuropathy in mice

    Ann. Neurol.

    (1991)
  • ArmstrongJ.G. et al.

    Initial clinical experience from leurocristine, a new alkaloid from Vinca rosea Linn.

  • BerndP. et al.

    Association of125I-nerve growth facor with PC12 pheochromocytoma cells: Evidence for internalization via high-affinity receptors only and for long term regulation by nerve growth factor of both high and low affinity receptors

    J. Biol. Chem.

    (1984)
  • BlackM.M. et al.

    Regulation of microtubule composition and stability during nerve growth factor-promoted neurite outgrowth

    (1986)
  • CaseyE.B. et al.

    Vincristine neuropathy: clinical and electrophysiological observations

    Brain

    (1973)
  • ChaoM.V. et al.

    Gene transfer and molecular cloning of the human NGF receptor

    Science

    (1986)
  • ChoE.-S. et al.

    Neurotoxicology of vincristine in the cat: morphological study

    Arch. Toxicol.

    (1983)
  • CrainS.M. et al.

    Enhanced dependence of fetal mouse neurons on trophic factors after taxol exposure in organotypic cultures

  • DanielsM.

    The role of microtubules in the growth and stabilization of nerve fibers

    Ann. NY Acad. Sci.

    (1975)
  • DrubinD.G. et al.

    Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors

    J. Cell. Biol.

    (1985)
  • Cited by (69)

    • Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems

      2020, Experimental Neurology
      Citation Excerpt :

      Based upon some early in vivo work, whereby NGF administration alleviated the neurotoxic effects of paclitaxel administration to rodents (Apfel et al., 1991), investigators endeavored to overcome the degenerative effects of chemotherapeutics by increasing growth factors in the in vitro culture media (Chen et al., 2017; Konings et al., 1994; Malgrange et al., 1994; Pittman et al., 2016). Although a protective effect of NGF was observed in embryonic neuronal explants treated with paclitaxel (Konings et al., 1994), these findings were not replicated in dissociated neurons derived from adult rats (Pittman et al., 2016), thus there might be a contribution of development in the protective effects of NGF on neuronal morphology. Other neuroprotective agents that have been found to inhibit or counteract the morphological changes of neurons induced by paclitaxel or docetaxel include insulin-like growth factor-1 (Chen et al., 2017), minoxidil (Chen et al., 2017), erythropoietin (Maggioni et al., 2010; Melli et al., 2006), and pirenzepine (Calcutt et al., 2017).

    • Hormesis: A potential strategic approach to the treatment of neurodegenerative disease

      2020, International Review of Neurobiology
      Citation Excerpt :

      These include Activating Dependent Neutrotrophic Factor (ADNF) (Brenneman et al., 2005), allixin and various derivatives (Moriguchi et al., 1996a, 1996b, 1997), allopregnanolone (Gago et al., 2004; O'Neill et al., 2004; Wang et al., 2005), various cannabinoids (Nagayama et al., 1999), and BDNF (Boyd and Gordon, 2002), bisphenol A (Gursoy et al., 2001), DHEA (Marx et al., 2000), fluvoxamine (Takebayashi et al., 2002) glucocorticoids (Abraham et al., 2000, 2001), glutamate (Bambrick et al., 1995), imipramine (Takebayashi et al., 2002), L-DOPA (levodopa) (Mena et al., 1997), lisuride (Gille et al., 2002), NMDA antagonists, such as AP5 and MK801 (Brenneman et al., 1990a), NO (Kim et al., 1999), raloxifene (O'Neill et al., 2004), spermine (Abe et al., 1993), VCF (Sondell et al., 1999), and VDH (Brewer et al., 2001). Furthermore, several agents have been shown to have hormetic-like biphasic dose responses for neurite outgrowth, including arachidonic acid (Konings et al., 1994), EPO (Bocker-Meffert et al., 2002), FGF (Williams et al., 1994a, 1994b), melanocortins (Joosten et al., 1995), NGF (Rosoff et al., 2004), VEGF (Sondell et al., 1999) and the immunosuppressive agents cyclosporin and staurosporine (Costantini and Isacson, 2000). Also well, low doses of the neurotoxic agents 6-OHDA (Kulich and Chu, 2001), mercuric chloride (HgCl) and methylmercury (Toimela and Tahti, 2004), and several pyrethroid mixtures (Kakko et al., 2004) have been shown to enhance markers of neuronal survival.

    • Nerve growth factor alters microtubule targeting agent-induced neurotransmitter release but not MTA-induced neurite retraction in sensory neurons

      2016, Experimental Neurology
      Citation Excerpt :

      Our findings demonstrate that NGF, even at a supraphysiological concentration (250 ng/ml), does not prevent or attenuate the effects of MTAs to decrease neurite length and branching in mature adult sensory neurons. These findings contrast with previous reports, which demonstrate an NGF-dependent reversal of the effects of MTAs when examining neurite outgrowth from embryonic DRG explants, adult superior cervical ganglion explants, or adult dissociated DRG cultures (Konings et al., 1994; Malgrange et al., 1994; Hayakawa et al., 1998). Importantly, we investigated the effects of the MTAs and NGF to alter retraction or degeneration from mature neurites of neurons derived from adult animals, whereas other studies have focused on neurite outgrowth from the soma of recently axotomized neurons.

    View all citing articles on Scopus
    View full text